Share
Share
Hemodialysis is a lifesaving procedure that requires a person to be connected to a dialysis machine by tubing that delivers fluid exchange. A vascular access is needed for this connection, with an arteriovenous fistula (AVF) or arteriovenous graft (AVG) being two common types of vascular access. AVFs and AVGs typically are surgically created in a patient’s arm but often require procedures to either become functional (during maturation phase) or maintain function after first use (maintenance phase). Using data from the United States Renal Data System (USRDS), our researchers calculated access procedure (intervention) rates in the US for patients starting hemodialysis with an AVF or AVG created during their first year of hemodialysis therapy between July 1, 2012 and December 31, 2014 (N = 73,027). Subsequent access-related procedures were included in analyses through Dec. 31, 2016. Interventions were common for both AVFs and AVGs as the access matured, with 13,989 of 57,275 (24.4%) AVFs requiring a procedure (0.36 AVF procedures/patient) and 2,904 of 15,572 (18.4%) AVG patients requiring intervention (0.28 AVG procedures/patient during maturation. However, during the maintenance phase, procedure rates were considerably lower for AVFs (0.93 procedures/patient occurring in 40% of patients) than for AVGs (1.87 procedures/patient occurring in 58% of patients). Thus, during maturation, interventions are carried out in 18-24% of newly created AVFs and AVGs. Once successfully matured, AVF had 50% lower maintenance interventional requirements.
The full text is available here: https://www.ajkd.org/article/S0272-6386(21)00511-4/fulltext
Citation
Woodside KJ, Repeck KJ, Mukhopadhyay P, Schaubel DE, Shahinian VB, Saran R, Pisoni RL. Arteriovenous Vascular Access-Related Procedural Burden Among Incident Hemodialysis Patients in the United States. Am J Kidney Dis. 2021 Apr 12:S0272-6386(21)00511-4. doi: 10.1053/j.ajkd.2021.01.019. Epub ahead of print. PMID: 33857533.
Arbor Research Collaborative for Health is excited to announce a partnership with CSL Vifor to launch a multinational registry designed to capture real-world outcomes of difelikefalin (Kapruvia®), a newly-approved treatment for chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis (HD) patients. Known as PARADIGM (PAn european Registry Addressing pruritus in DIalysis with a focus on Goal […]
The Health Resources and Services Administration (HRSA) has selected Arbor Research Collaborative for Health (Arbor Research) as one of 14 organizations who will lead the modernization of the Organ Procurement and Transplantation Network (OPTN). Arbor Research received one of the five initial efforts, focusing on improving patient safety and policy compliance systems and processes overseen […]
Arbor Research Collaborative for Health (Arbor Research) is proud to announce that its wholly-owned, small-business subsidiary, Arbor Research LLC, received its first competitive prime contract award. The award expands the organization’s 25-year history doing mission-impactful work in chronic disease and beyond. Arbor Research was awarded the National Cancer Institute (NCI) Center for Global Health (CGH) […]
Arbor Research Collaborative for Health, a Michigan-based 501(c)3 nonprofit corporation, is proud to announce the award of the General Services Administration (GSA) Multiple Award Schedule contract to its subsidiary, Arbor Research LLC under SINs 541611 and 541715. Arbor Research LLC qualifies as a small business under the associated NAICS codes and will seek additional SINs […]